Related Experiment Video
Updated: May 20, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
MRl of prostate cancer antigen expression for diagnosis and immunotherapy
Jing Ren1, Fang Wang, Guangquan Wei
1Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xian, China.
Background:
Tumor antigen (TA)-targeted monoclonal antibody (mAb) immunotherapy can be effective for the treatment of a broad range of cancer etiologies; however, these approaches have demonstrated variable clinical efficacy for the treatment of patients with prostate cancer (PCa). An obstacle currently impeding translational progress has been the inability to quantify the mAb dose that reaches the tumor site and binds to the targeted TAs. The coupling of mAb to nanoparticle-based magnetic resonance imaging (MRI) probes should permit in vivo measurement of patient-specific biodistributions; these measurements could facilitate future development of novel dosimetry paradigms wherein mAb dose is titrated to optimize outcomes for individual patients.
Methods:
The prostate stem cell antigen (PSCA) is broadly expressed on the surface of prostate cancer (PCa) cells. Anti-human PSCA monoclonal antibodies (mAb 7F5) were bound to Au/Fe(3)O(4) (GoldMag) nanoparticles (mAb 7F5@GoldMag) to serve as PSCA-specific theragnostic MRI probe permitting visualization of mAb biodistribution in vivo. First, the antibody immobilization efficiency of the GoldMag particles and the efficacy for PSCA-specific binding was assessed. Next, PC-3 (prostate cancer with PSCA over-expression) and SMMC-7721 (hepatoma cells without PSCA expression) tumor-bearing mice were injected with mAb 7F5@GoldMag for MRI. MRI probe biodistributions were assessed at increasing time intervals post-infusion; therapy response was evaluated with serial tumor volume measurements.
Results:
Targeted binding of the mAb 7F5@GoldMag probes to PC-3 cells was verified using optical images and MRI; selective binding was not observed for SMMC-7721 tumors. The immunotherapeutic efficacy of the mAb 7F5@GoldMag in PC-3 tumor-bearing mice was verified with significant inhibition of tumor growth compared to untreated control animals.
Conclusion:
Our promising results suggest the feasibility of using mAb 7F5@GoldMag probes as a novel paradigm for the detection and immunotherapeutic treatment of PCa. We optimistically anticipate that the approaches have the potential to be translated into the clinical settings.
Insights
This study developed a novel theragnostic MRI probe (mAb 7F5@GoldMag) for prostate cancer (PCa). The probe successfully visualized antibody biodistribution and demonstrated immunotherapeutic efficacy, inhibiting tumor growth in mice.
Area of Science:
- Nanotechnology in Medicine
- Oncology
- Immunotherapy
Background:
- Monoclonal antibody (mAb) immunotherapy shows variable efficacy in prostate cancer (PCa).
- Quantifying mAb dose at the tumor site is a significant challenge for PCa treatment.
- Nanoparticle-based MRI probes can enable in vivo measurement of mAb biodistribution for personalized dosimetry.
Purpose of the Study:
- To develop a PSCA-specific theragnostic MRI probe for visualizing mAb biodistribution in vivo.
- To assess the targeted binding and immunotherapeutic efficacy of the developed probe in PCa models.
Main Methods:
- Anti-PSCA mAb 7F5 was conjugated to Au/Fe(3)O(4) (GoldMag) nanoparticles, creating mAb 7F5@GoldMag.
- The probe's binding specificity was tested on PC-3 (PSCA-positive) and SMMC-7721 (PSCA-negative) tumor models in mice.
- MRI was used to track probe biodistribution, and tumor growth was monitored to evaluate therapeutic response.
Main Results:
- mAb 7F5@GoldMag demonstrated targeted binding to PC-3 cells, confirmed by optical imaging and MRI.
- Selective binding was not observed in SMMC-7721 tumors.
- Significant inhibition of tumor growth was observed in PC-3 tumor-bearing mice treated with the probe.
Conclusions:
- mAb 7F5@GoldMag probes show feasibility as a novel paradigm for PCa detection and immunotherapy.
- This theragnostic approach has potential for clinical translation in PCa treatment.
- In vivo visualization of mAb biodistribution could lead to optimized, patient-specific immunotherapy dosing.
